TCS shares fall nearly 5% after Q1 earnings; mcap declines by ₹55,471 crore
The Hindu
TCS has missed on both revenue and margins in the June quarter results, says expert
Shares of Tata Consultancy Services (TCS) on Monday fell nearly 5%, wiping out ₹55,471.22 crore from its market valuation, after the company's June quarter earnings failed to meet market expectations.
The stock declined 4.64% to settle at ₹3,113.25 apiece on the BSE. During the day, it went lower by 4.87% to ₹3,105.85.
On the NSE, it fell 4.70% to end at ₹3,112 apiece.
Its market capitalisation (mcap) tumbled ₹55,471.22 crore to ₹11,39,154.17 crore on the BSE.
"On a stock specific front TCS fell by more than 4% as Q1 FY23 results missed estimates," said Mohit Nigam, Head - PMS at Hem Securities.
The country's largest software exporter TCS on Friday reported a 5.2% rise in the June quarter net profit to ₹9,478 crore, restricted by the impact of annual wage hikes and promotions that took operating profit margins to multi-quarter lows.
The Tata Group company, which is the first in the country's over $220 billion software exports industry to report earnings, however, said that it does not see any adverse business impact because of worries around recession in its key markets.
Gold and silver prices surge to record highs as investors seek safe havens amid geopolitical tensions and rate-cut expectations.
Stock markets decline after two days of gains, with subdued trading expected amid a holiday-shortened week.
Rupee dips to 89.73 against the dollar as Sensex and Nifty also decline amid FII outflows and weak market conditions.
Mercedes-Benz settles multistate emissions allegations for $149.6 million, addressing illegal devices in over 211,000 vehicles.
U.S. approves Wegovy pill for weight loss, expanding access to obesity treatment with a convenient daily oral option.
RBI Bulletin highlights resilient economic activity in India, driven by robust demand, despite challenges in external trade and inflation.
Biofabri and Bharat Biotech partner to advance MTBVAC, a tuberculosis vaccine, ensuring equitable access and manufacturing readiness in India.
India anticipates doubling trade with New Zealand to $5 billion in five years following a historic women-led free trade agreement.
Rupee dips 3 paise to 89.70 against the dollar amid trade deal concerns and rising crude oil prices.
Government to release new series of retail inflation, GDP data from February, IIP from May next year
The Indian government will release new macroeconomic data series, including GDP and inflation, starting February 2026.
Granules India secures U.S. FDA tentative approval for its ADHD generic, enhancing access to critical therapy and expanding its generics portfolio.
Italy’s competition authority (AGCM) said on Monday it had fined U.S technology giant Apple and two of its divisions 98.6 million euros ($115.53 million) over alleged abuse of their dominant position in the mobile app market.
India denies duty concessions on dairy imports from New Zealand in recent trade pact negotiations, prioritizing local farmers' protection.